Sun to raise $1.5 billion for M&A; spotlight on Stada, potential biosimilars interest
This article was originally published in Scrip
Executive Summary
Sun Pharmaceutical Industries may be moving away from its conservative approach to mergers and acquisitions, if its latest fund-raising plan is anything to go by.